Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETAreceptor antagonist

Author： Tilton R.G.   Munsch C.L.   Sherwood S.J.   Chen S-J.   Chen Y-F.   Wu C.   Block N.   Dixon R.A.F.   Brock T.A.  

Publisher： Academic Press

ISSN： 1094-5539

Source： Pulmonary Pharmacology & Therapeutics, Vol.13, Iss.2, 2000-04, pp. : 87-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of ETAReceptor Antagonist on Pulmonary Hypertension and Vascular Reactivity in Rats With Congestive Heart Failure

By Lucas M.   Jasmin J.F.   Dupuis J.  

Pulmonary Pharmacology & Therapeutics, Vol. 14, Iss. 4, 2001-08 ,pp. : 307-314

Academic Press

Access to resources Recommend Favorite

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

By Horn Evelyn M   Widlitz Allison C   Barst Robyn J  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1483-1492

Informa Healthcare

Access to resources Recommend Favorite

ZD1611, an Orally Active Endothelin-A Receptor Antagonist, Prevents Chronic Hypoxia-induced Pulmonary Hypertension in the Rat

By Bialecki R.A.   Fisher C.S.   Abbott B.M.   Barthlow H.G.   Caccese R.G.   Stow R.B.   Rumsey J.   Rumsey W.  

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 5, 1999-10 ,pp. : 303-312

Academic Press

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Sitaxsentan STRIDEs ahead in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite